TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under EFR 1.97(b) or 1.97(c))						Docket No. RLL-262US		
In Re Application Of: GOGIA et al.								
Applic	ation No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.		
10/5	518,972		Unknown	26815	Unknown	2913		
Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS								
Address to:  Commissioner for Patents  P.O. Box 1450  Alexandria, VA 22313-1450								
_ 0,0			37 CFR 1.97(b)					
1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.								
			37 CFR 1.97(c)					
2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:								
☐ the statement specified in 37 CFR 1.97(e);								
OR								
	☐ the	fee set forth in 37 CF	FR 1.17(p).					

TRANSMITTA	(Unde	ATION DISCLOS R 1.97(b) or 1.97(		ATEMENT	III	cket No. L-262US
In Re Applicatio	n: GOGIA et al.					
Application No.	Filing Date	Examine	r	Customer No.	Group Art Unit	Confirmation No.
10/518,972		Unknowi	1	26815	Unknown	2913
	FOR THE PREPARALORIDE TABLETS			ATIONS OF V	ALACYCLOVII	<b>R</b>
	(Only cor	Paymo nplete if Applicant elec	ent of Fee ts to pay the f	fee set forth in 37	CFR 1.17(p))	
☐ The Director as described as described ☐ Ch ☐ Cre ☐ Ch ☐ Ch ☐ Payment by WARNING included of Certific:  ☐ I certify that this account is being	the amount of or is hereby authorize	is attaced to charge and creed.  t. ee required. TO-2038 is attached a form may become credit card information to charge deposit	d. d. e public. Conation and  Ce  I hereby with the Las first "Commiss 22313-145"	Account No. 5  Fredit card info authorization  rtificate of Mail  certify that this could states Postaliae mail in sioner for Patents, 50" [37 CFR 1.8(a)]	ormation should on PTO-2038.  ling by First Clastorespondence is being an envelope an P.O. Box 1450, Ale	ng deposited cient postage ddressed to exandria, VA
	Signature				tine Kenedy	)······
L	Printed Name of Person Sig		Тур	ed or Printed Name	of Person Mailing Co	ertificate
*This certific deposit according to the deposi	ate may only be used unt.  Signature	if paying by	Dated:	January 18, 200	06	
cc:			·			

INFORMATION DISC	SURE	CITATIO	N
	,		

Docket No.: RLL-262US

Serial No.: 10/518,972

Applicants:

GIA et al.

Filed: 12/21/2004

Group:

			U.S. P	ATENT DOCUMENTS	6		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,957,924	9/18/1990	Beauchamp	514	262	
	A2	5,879,706	3/9/1999	Carter et al.	424	464	
	A3	6,107,302	8/22/200	Carter <i>et al.</i>	514	262	
			FOREIGN	N PATENT DOCUMEN	ITS		
		DOCUMENT NUMBER	· DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	B1	WO 96/22082	7/25/1996	PCT	A61K	9/20	
	B2	WO 96/22291	7/25/1996	PCT	C07D	473/00	
	В3	WO 96/32097	10/17/1996	PCT	A61K	9/20	
	B4	WO 97/25989	7/24/1997	PCT	A61K	31/52	
	B5	WO 03/022209	3/20/2003	PCT	A61K		
	B6	EP 0 308 065	3/22/1989	EPO	C07D	473/18	
		OTHER DOCUME	NTS (Includ	ling Author, Title, Date	, Pertinent Pa	ages, Etc.)	
	C1	Beauchamp et al. Chemotherapy, 3	, "Amino ac (3):157-164	id ester prodrugs of ac (1992)	cyclovir", <i>Anti</i>	viral Chemi	stry and

EX/	٩M	IN	ER	

**DATE CONSIDERED** 

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.